Corient Private Wealth’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.84M | Buy |
12,142
+6,986
| +135% | +$1.06M | ﹤0.01% | 1137 |
|
|
2025
Q1 | $776K | Sell |
5,156
-2,926
| -36% | -$440K | ﹤0.01% | 1387 |
|
|
2024
Q4 | $1.49M | Sell |
8,082
-3,876
| -32% | -$716K | ﹤0.01% | 1124 |
|
|
2024
Q3 | $2.36M | Sell |
11,958
-328
| -3% | -$64.6K | ﹤0.01% | 1002 |
|
|
2024
Q2 | $2.54M | Buy |
12,286
+2
| +0% | +$413 | ﹤0.01% | 926 |
|
|
2024
Q1 | $3.33M | Sell |
12,284
-1,074
| -8% | -$291K | 0.01% | 820 |
|
|
2023
Q4 | $3.16M | Buy |
13,358
+7,127
| +114% | +$1.68M | 0.01% | 829 |
|
|
2023
Q3 | $1.22M | Buy |
6,231
+2,713
| +77% | +$532K | ﹤0.01% | 1120 |
|
|
2023
Q2 | $740K | Buy |
3,518
+372
| +12% | +$78.2K | ﹤0.01% | 1262 |
|
|
2023
Q1 | $635K | Buy |
3,146
+316
| +11% | +$63.8K | ﹤0.01% | 1274 |
|
|
2022
Q4 | $617K | Buy |
+2,830
| New | +$617K | ﹤0.01% | 1071 |
|